Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

News articleYahoo Finance· January 30, 2026

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Regeneron Pharmaceuticals, Inc…

Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Libtayo is the leading immunotherapy for non-melanoma skin cancers
80% confidence
Libtayo is first and only immunotherapy approved for high-risk adjuvant cutaneous squamous cell carcinoma
80% confidence
Regeneron has announced $7B+ in ongoing and planned domestic investments
80% confidence
Dupixent has 1.4M+ active patients worldwide
80% confidence
EYLEA sales decline driven by competitive pressures, compounded bevacizumab market share loss due to patient affordability constraints, patient transition to EYLEA HD, and lower net selling price
80% confidence
Dupixent is the most widely used innovative branded antibody medicine worldwide
80% confidence
Regeneron has approximately 45 product candidates in clinical development
80% confidence